GHTC submitted written testimony to the House State, Foreign Operations, and Related Programs Appropriations Subcommittee urging them to sustain and protect global health R&D funding in the fiscal year 2022 budget.PDF
GHTC releases a new policy report which provides an agency-by-agency blueprint for US policymakers to supercharge global health R&D in the wake of the COVID-19 pandemic that has revealed both the sector’s chronic neglect and amazing potential.Learn more
GHTC released a recent report exploring how COVID-19 is impacting the global health R&D sector. Based on qualitative interviews, it looks at both immediate impacts, including disruptions to research and diversion of funding and expertise, as well as long-term challenges and opportunities that may reshape the sector in the years to come.Learn more
FIND, the global alliance for diagnostics, recently hosted a high-level forum, Testing is the first line of defence against COVID-19 and the foundation for preparedness to prevent future pandemics, featuring distinguished guests Dr. Tedros, WHO; Peter Sands, Global Fund; and FIND Goodwill Ambassador Dr. Aminata Touré to explore how COVID-19 has transformed testing, implications for diagnostics in health emergencies and universal health coverage, and how this has informed the newly published FIND 2021 strategy.
Why we're needed
Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.Learn More
GHTC delivers statement on the global strategy on health, innovation, and intellectual property at the World Health Assembly
GHTC delivered a statement at the 74th World Health Assembly calling on the World Health Organization and member states to strengthen the capacity of national and regional regulatory functions and systems. The statement, issued through the Global Health Council, also urges member states to support a resolution to strengthen local production of medicines and health technologies, as well as ensure better regional collaboration for regulatory functions.Learn more
GHTC joined a civil society statement at the 74th World Health Assembly calling on the World Health Organization (WHO) and member states to strengthen vaccine-related research and innovation with the most vulnerable populations in mind and increase investment in R&D for new health technologies to fight antimicrobial resistance (AMR). The statement, issued through the Global Health Council, urges WHO and member states to support research on the full spectrum of product needs, including vaccine administration, storage, and delivery innovations, as well as new antimicrobials, diagnostics, and vaccines to address the threat of AMR.Learn more
Consortium of Universities for Global Health
Global Antibiotic Research and Development Partnership
Research Roundup: Novavax and CureVac release vaccine efficacy data, Regeneron antibody cuts deaths in some hospitalized patients
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
Biden budget proposes boosts to research and health security spending but falls short on broader global health needs
In late May, the Biden-Harris administration released its detailed fiscal year 2022 budget request. Here's our breakdown of the details of the proposal and initial takeaways of how, if enacted, it could impact global health research and development programming.